Recent Updates — GTBP

GT Biopharma, Inc. amended its Securities Purchase Agreement to increase the private placement of Series M 10% Convertible Preferred Stock and accompanying warrants. A new purchaser joined the offering on September 18, 2026, raising the aggregate purchase price from $7,450,000 to $7,750,000 for 8,611.111 shares of preferred stock with a stated value of $8,611,111.11. The company also filed a Certificate of Increase in Delaware, raising the authorized number of Series M shares from 41,778 to 43,287. Investors retain Greenshoe Rights to purchase up to an additional $34,675,615 in stated value for $31,208,054. The company operates in the biotechnology industry, focusing on developing immunotherapies.

GT Biopharma, Inc. entered into a Securities Purchase Agreement on September 14, 2026, for the private placement of Series M 10% Convertible Preferred Stock and warrants with an aggregate purchase price of $7,450,000. The offering includes up to 8,277.778 shares of preferred stock convertible at $6.10 per share, along with common and vesting warrants exercisable at the same price for five years. Purchasers hold Greenshoe Rights to purchase an additional $30,000,000 in stated value. The preferred stock accrues cumulative dividends at 10% annually until September 2027, increasing to 12% thereafter, payable quarterly. GT Biopharma operates in the biotechnology industry, focusing on developing immunotherapies for cancer treatment.

GT Biopharma, Inc. filed Certificates of Elimination to remove all outstanding series of preferred stock from its Charter and a Certificate of Amendment to effect a 1-for-25 reverse stock split of its common stock effective September 8, 2026. The split reduces issued shares from approximately 45.1 million to roughly 1.8 million and lowers authorized capital stock from 265 million to 26.5 million shares. This action follows shareholder approval at the August 14, 2026 annual meeting. GT Biopharma operates in the biotechnology industry, focusing on developing immunotherapies for cancer treatment.

GT Biopharma, Inc. held its Annual Meeting of Stockholders on August 14, 2026, where shareholders approved several key proposals. The meeting resulted in the election of four directors: Michael Breen, Charles J. Casamento, Hilary Kramer, and David C. Mun-Gavin. Shareholders also ratified Weinberg & Company, P.A. as independent accountants and approved a non-binding advisory vote on executive compensation. Significantly, stockholders authorized an amendment to the restated certificate of incorporation to permit a reverse stock split at a ratio between 1-for-10 and 1-for-30, alongside a reduction in authorized common shares to 25,000,000 and preferred shares to 1,500,000. The Board retains discretion to determine the specific split ratio and effective date within one year. Additionally, shareholders approved an increase of 3,500,000 shares in the 2022 Omnibus Incentive Plan and adopted an evergreen provision for automatic annual increases. GT Biopharma operates as a clinical-stage biotechnology company focused on developing immunotherapies.

GT Biopharma, Inc. amended its bylaws-to-reduce the quorum requirement for stockholder-to-meetings. The Board of Directors approved an amendment effective June 8, 2026, which reduced the holders of not less than one-third (1/3) of outstanding shares to constitute a quorum. This change was implemented to address difficulty in obtaining a majority quorum due to brokerage firms opting to forgo discretionary voting of shares held in street name. GT Biopharma, Inc. is a biotechnology company focused on research and development of biological products.